Feedback / Questions
225Ac-vipivotide tetraxetan (AAA817) - Novartis
AAA817: Regulatory submission for post Lu mCRPC in 2028
(Novartis)
-
Jul 21, 2026 -
Q2 2026 Results: Regulatory submission for 1L mCRPC in 2029 or later
Filing
•
Castration-Resistant Prostate Cancer • Oncology
https://www.novartis.com/sites/novartis_com/files/q2-2026-investor-presentation.pdf
Jul 21, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious